Ningbo Menovo Pharmaceutical Co (SHSE:603538) Tariff Resilience Score: 0/10 (As of Aug. 08, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:603538 Ningbo Menovo Pharmaceutical Co Ltd SHSE:603538
64 GF Score
Price ¥29.20
GF Value ¥16.50
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Ningbo Menovo Pharmaceutical Co Tariff Resilience Score?

Ningbo Menovo Pharmaceutical Co has the Tariff Resilience Score of 0, which implies that the company might have .

Ningbo Menovo Pharmaceutical Co has

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Ningbo Menovo Pharmaceutical Co might have .

Ningbo Menovo Pharmaceutical Co  (SHSE:603538) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Ningbo Menovo Pharmaceutical Co Tariff Resilience Score Related Terms

SHSE:603538
64GF Score
Ningbo Menovo Pharmaceutical Co Ltd SHSE:603538
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Ningbo Menovo Pharmaceutical Co (SHSE:603538) Overvalued in 2026?

Based on GuruFocus' analysis, Ningbo Menovo Pharmaceutical Co stock appears to be overvalued. The current stock price of ¥29.20 is trading 77% above its estimated GF Value™ of ¥16.50. GuruFocus considers Ningbo Menovo Pharmaceutical Co to be Significantly Overvalued.

Key valuation signals for SHSE:603538:

  • Tariff Resilience Score: 0
  • GF Value™: ¥16.50 vs. price of ¥29.20 (77% above fair value)
  • GF Score™: 64/100 with 6 warning signs

No single metric tells the full story. See the SHSE:603538 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ningbo Menovo Pharmaceutical Co Business Description

Address No.999,Yangfan Road, Room 1406, No.1, High-tech Zone, Ningbo, CHN, 315040
Ningbo Menovo Pharmaceutical Co Ltd is a China-based company is engaged in the research and development, pilot, production and sales of pharmaceutical intermediates, APIs and finished drugs. Its products line includes cardiovascular, central nervous, respiratory, anti-tumor, anti-infective, digestive system, geriatric diseases and anti-viral systems.
64GF Score

Get the complete analysis for SHSE:603538

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥29.20
Price
¥16.50
GF Value